Technology ID
TAB-4907
Enhancing Vaccine Efficacy: The Role of HA-Ferritin Nanoparticle Mutation in Protein Production
E-Numbers
E-094-2014-0
Lead Inventor
Kanekiyo, Masaru
Lead IC
NIAID
Co-Inventors
Graham, Barney
Nabel, Gary
Whittle, James
ICs
NIAID
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Stages
Analytical Assay Performance Stage
Research Products
Research Equipment
The technology involves the development of viral hemagglutinin (HA) mutants that enhance the binding affinity to sialic acid (SA) receptors on host cell surfaces. This enhanced interaction is achieved by introducing specific mutations into the HA protein, leading to increased immunogenicity and vaccine efficacy. The mutated HA proteins are then incorporated into ferritin nanoparticles, which serve as a delivery platform to enhance protein production and stability. This technology shows promise in improving vaccine design and efficacy against viral infections.
Commercial Applications
This technology has the potential to revolutionize vaccine development for a range of viral infections. By enhancing the immunogenicity of vaccines through improved HA-SA binding, it could lead to more effective vaccines against influenza, Zika virus, and other diseases. The use of ferritin nanoparticles also opens up possibilities for developing vaccines against other pathogens, including bacteria and parasites. Additionally, this technology could be applied to enhance existing vaccines, improving their efficacy and potentially reducing the need for frequent updates.
Competitive Advantages
This technology offers competitive advantages by enhancing vaccine immunogenicity through improved HA-SA binding affinity and increased protein stability using ferritin nanoparticles. These advantages could lead to more effective vaccines, targeted against specific viral strains, and potentially reduce the risk of viral escape mutants.
Licensing Contact: